<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01002703</url>
  </required_header>
  <id_info>
    <org_study_id>RBP-01/08</org_study_id>
    <secondary_id>OSHO77</secondary_id>
    <nct_id>NCT01002703</nct_id>
  </id_info>
  <brief_title>Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Define maximum tolerable dose of the combination lenalidomide, bendamustine, prednisone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerable dose (MTD) of lenalidomide in combination with bendamustine and prednisone (RBP) in refractory and relapsed MM stage I/III</measure>
    <time_frame>2 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety of lenalidomide, bendamustine and prednisone at MTD</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>RBP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide and Bendamustine and Prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Bendamustine, Prednisone</intervention_name>
    <description>During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.</description>
    <arm_group_label>RBP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Understand and voluntarily sign an informed consent form.

          2. Age 18 years at the time of signing the informed consent form.

          3. Life expectancy of at least 3 months

          4. Able to adhere to the study visit schedule and other protocol requirements

          5. Relapsed or refractory MM (only first or second relapse) in stage II or III after
             autologous SCT or conventional chemotherapy (histologically or cytologically proven/
             Salmon and Durie criteria) with detectable myeloma protein in blood or urine

          6. All previous cancer therapies, including radiation, cytostatic therapy and surgery,
             must have been discontinued at least 4 weeks prior to treatment in this study, without
             corticosteroids therapy.

          7. ECOG performance status of £ 2 at study entry (see Appendix 01).

          8. Laboratory test results within ranges

          9. Females of childbearing potential must agree to contraception or abstinence

         10. Disease free of prior malignancies for ³ 5 years with exception of currently treated
             basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;insitu&quot; of the cervix
             or breast

        Exclusion Criteria:

          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          2. Pregnant or breast feeding females.

          3. Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          4. Patients with contraindications (exclusion criteria) for treatment with lenalidomide,
             bendamustine and prednisone.

          5. Uncontrolled or severe cardiovascular disease, including myocardial infarction within
             6 months before study entry, New York Heart Association Class III or IV heart failure,
             uncontrolled angina or severe uncontrolled ventricular arrhythmias (≥ Lown 3).

          6. Use of any other experimental drug or therapy within 28 days of baseline.

          7. Known hypersensitivity to thalidomide or purine analogues

          8. The development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs.

          9. Any prior use of lenalidomide or bendamustine in the last six months

         10. Concurrent use of other anti-cancer agents or treatments other stated in this
             treatment plan.

         11. Known positive for HIV or infectious hepatitis, type A, B or C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dietger Niederwieser</last_name>
    <phone>+4934197</phone>
    <phone_ext>13050</phone_ext>
    <email>dietger@medizin.uni-leipzig.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser</last_name>
      <phone>+4934197</phone>
      <phone_ext>13050</phone_ext>
      <email>dietger@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Wolfram Pönisch</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://osho.uni-leipzig.de/</url>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <last_update_submitted>August 11, 2011</last_update_submitted>
  <last_update_submitted_qc>August 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 12, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Dr. h.c. Dietger Niederwieser</name_title>
    <organization>University of Leipzig</organization>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Myeloma</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Phase I/II</keyword>
  <keyword>refractory Myeloma</keyword>
  <keyword>relapsed Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

